N06BC01 caffeine
NERVOUS SYSTEM ›PSYCHOANALEPTICS ›PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS ›Xanthine derivatives
健保收載品項 FDA 已核准 TFDA 在效許可證 7 健保給付條款 1
健保收載品名:"嘉林"賜爾蘇膠囊、"大豐"安那加注射液100公絲/公撮(咖啡鹼笨甲酸鈉)、"應元"安鈉咖注射液25%、"汎生"心榮健 注射液 100 毫克/毫升、咖啡鹹苯甲酸鈉注射液、啡那輸注溶液及口服液、安鈉咖針25%
FDA 適應症
1 INDICATIONS AND USAGE Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions ( 5.1 )] , reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options [e.g., non-opioid, non-barbiturate analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsule is a combination product of butalbital, a barbiturate; acetaminophen; caffeine, a methylxanthine; and codeine phosphate, an opioid agonist; and is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesic and alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options (e.g., non-opioid, non-barbiturate analgesics): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
資料來源:openFDA(美國 FDA Structured Product Labeling)。為英文原文,僅供對照。
TFDA 適應症
NHI 給付規定
直接適用條款
§ 6.2.11 Caffeine citrate (如Peyona):(115/1/1)
呼吸道藥物 › 其他
Caffeine citrate (如Peyona):(115/1/1) 1.用於治療原發性早產兒呼吸暫停。 2.治療條件:受孕後週數(postmenstral age, PMA)未滿35週(35+0)早產兒,經臨床診斷具顯著呼吸暫停或心搏過緩情形。 3.停用時機(符合下列任一情形): (1)受孕後週數(postmenstral age, PMA)33+0週以前,停用正壓呼吸器後,持續觀察5至7天,無臨床顯著呼吸暫停或心搏過緩發生,則停止用藥。 (2)受孕後週數(postmenstral age, PMA)33+0至35+0週,無臨床顯著呼吸暫停或心搏過緩發生,則停止用藥。
歷史演變(4 次異動)
| 生效日 | 異動說明 |
|---|---|
| 91/8/1 | legacy_boan_parsed:ch06.txt |
| 111/3/1 | legacy_boan_parsed:ch06.txt |
| 113/8/1 | legacy_boan_parsed:ch06.txt |
| 115/1/1 | legacy_boan_parsed:ch06.txt |
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
FDA 段:openFDA US SPL · TFDA 段:食藥署西藥許可證+ATC 分類開放資料 · NHI 段:健保署「全民健康保險藥品給付規定」(更新日 2026-05-31)· 實證補充段:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。